Using HIFU to treat prostate cancer
High-Intensity Focused Ultrasound for Focal Ablation of Prostate Tissue: An Observational Study of Multiparametric MRI and Ultrasound Fusion Imaging for Guidance
This study looks at how well High Intensity Focused Ultrasound (HIFU) works for treating prostate cancer and how it affects patients' quality of life before and after the treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 40 Years to 85 Years |
| Sex | Male |
| Sponsor | University of California, Los Angeles Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT03620786 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the effectiveness of High Intensity Focused Ultrasound (HIFU) for the localized treatment of prostate cancer. Participants will have already chosen or undergone HIFU therapy as part of their standard care. The study will collect clinical data and health-related quality of life (HRQOL) information through medical record reviews and questionnaires before and after the HIFU procedure. The goal is to assess the outcomes and experiences of patients receiving this treatment.
Who should consider this trial
Good fit: Ideal candidates are men aged 40 to 85 who have elected to receive HIFU therapy for prostate cancer and have declined other treatment options.
Not a fit: Patients who have previously undergone treatment for prostate cancer or have medical contraindications to follow-up procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness and quality of life outcomes associated with HIFU treatment for prostate cancer.
How similar studies have performed: Other studies have shown promise with HIFU for prostate cancer, indicating that this approach has potential based on previous findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 40 years to 85 years 2. Subject has elected or already undergone HIFU therapy as their standard of care treatment methodand declined alternative treatment (active surveillance, radical prostatectomy, radiation therapy, cryosurgery and hormone therapy) 3. PSA ≤ 20 4. Prostate volume of ≤ 70 cc 5. Ability to complete informed consent form Exclusion Criteria: 1. Prior treatment for prostate cancer (with the exception of androgen deprivation therapy) 2. Medical contraindication to follow-up mpMRI or prostate biopsy 3. Unable to tolerate general or regional anesthesia 4. Positive bone scan (only if bone scan has been done or clinically indicated. Bone scan does not need to be performed for study eligibility determination.)
Where this trial is running
Los Angeles, California
- University of California, Los Angeles — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Leonard Marks, MD — University of California, Los Angeles
- Study coordinator: Michelle C Cardenas, MSN, NP
- Email: mccardenas@mednet.ucla.edu
- Phone: (310) 794-3070
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.